A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

Patnaik Amita; Gordon Michael; Tsai Frank; Papadopoulos Kyriakos P.; Rasco Drew; Beeram Muralidhar; Fu Siqing; Janku Filip; Hynes Scott M.; Gundala Sushma R.; Willard Melinda D.; Zhang Wei; Lin Aimee Bence; Hong David

首页> 外文期刊>Cancer chemotherapy and pharmacology. >A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

【24h】

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

机译：患有先进或转移性癌症的患者（Vol 82，PG 407,2018）的患者靶向患者和EGFR的双特异性抗体，靶向抗体，靶向患者和EGFR的阶段研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The original version of this article unfortunately contained a mistake. The co-authors' names were incorrect.

机译：本文的原始版本遗憾的是含有一个错误。共同作者的名字不正确。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2018年第3期|共1页
作者
Patnaik Amita; Gordon Michael; Tsai Frank; Papadopoulos Kyriakos P.; Rasco Drew; Beeram Muralidhar; Fu Siqing; Janku Filip; Hynes Scott M.; Gundala Sushma R.; Willard Melinda D.; Zhang Wei; Lin Aimee Bence; Hong David;
展开▼
作者单位

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

HonorHlth Res Inst Scottsdale AZ USA;

HonorHlth Res Inst Scottsdale AZ USA;

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

START 4383 Med Dr Suite 4026 San Antonio TX 78229 USA;

Univ Texas MD Anderson Canc Ctr Canc Med Div Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Canc Med Div Houston TX 77030 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Univ Texas MD Anderson Canc Ctr Canc Med Div Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018) [J] . Patnaik Amita, Gordon Michael, Tsai Frank, Cancer chemotherapy and pharmacology. . 2018,第3期

机译：I阶段I的Ly3164530研究，靶向患者和转移性癌症患者（Vol 82，PG 407,2018）的靶向患者和EGFR的双特异性抗体研究
2. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018) [J] . Patnaik Amita, Gordon Michael, Tsai Frank, Cancer chemotherapy and pharmacology. . 2018,第3期

机译：患有先进或转移性癌症的患者（Vol 82，PG 407,2018）的患者靶向患者和EGFR的双特异性抗体，靶向抗体，靶向患者和EGFR的阶段研究
3. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer [J] . Patnaik Amita, Gordon Michael, Tsai Frank, Cancer chemotherapy and pharmacology. . 2018,第3期

机译：I阶段研究Ly3164530，靶向患者和转移性癌症患者的双特异性抗体，靶向患者和EGFR
4. The Benefits of Bispecific mAb-square Antibodies Targeting EGFR and HGF [C] . Melanie Medcalf, Kin-Mei Leung, Samine Isaac, Protein Engineering Summit. . 2018

机译：靶向EGFR和HGF的双特异性mAB-方抗体的益处
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A phase I study of LY3164530 a bispecific antibody targeting MET and EGFR in patients with advanced or metastatic cancer [O] . Amita Patnaik, Michael Gordon, Frank Tsai, -1

机译：一项针对MET和EGFR的双特异性抗体LY3164530在患有晚期或转移性癌症的患者中进行的I期研究
7. Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS) [O] . 2015

机译：五名晚期胰腺癌患者在抗CD3 x抗EGFR双特异性抗体武装的活化T细胞（BATS）的I期研究中

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (vol 82, pg 407, 2018)

摘要

著录项

相似文献

相关主题

期刊订阅